Xiaoying Zhao

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov et al. · Blood · 2013 · 679 citations · Full text

Medicine, Cancer Biology, Oncology +15

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Zijun Y. Xu‐Monette, Lin Wu, Carlo Visco et al. · Blood · 2012 · 391 citations · Full text

Medicine, Hematology, Oncology +14

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Shimin Hu, Zijun Y. Xu‐Monette, Aarthi Balasubramanyam et al. · Blood · 2013 · 246 citations · Full text

Medicine, Hematology, Oncology +14

Clinical and biological significance of<i>de novo</i>CD5+ diffuse large B-cell lymphoma in Western countries

Zijun Y. Xu‐Monette, Meifeng Tu, Kausar J. Jabbar et al. · Oncotarget · 2015 · 92 citations · Full text

Medicine, Hematology, Oncology +17

Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma

Jiayu Chen, Zijun Y. Xu‐Monette, Lijuan Deng et al. · Oncotarget · 2015 · 80 citations · Full text

Medicine, Immunology, Oncology +15